Condition: Recurrent Non-small Cell Lung Cancer · Sponsor: Shanghai Jiao Tong University School of Medicine
The purpose of this study is to determine if the commonly administered chemotherapeutic agents including cisplatin, carboplatin, oxaliplatin, docetaxel and gemcitabine for solid tumors in clinical oncology, either a single format or given as combinations followed by surgery are effective in the treatment of relapsed and refractory non-small cell lung cancer patients.
This description comes directly from the study's public registry record.
Yu Sun, Ph.D · 86-21-54923302 · sunyu@sibs.ac.cn
Weijun Ma, Ph.D · 86-21-54923268 · wjma@sibs.ac.cn
Always discuss trial participation with your own doctor first.
| China-Japan Union Hospital, Jilin University | Changchun, Jilin, China | Recruiting |
| Shanghai 10th People's Hospital | Shanghai, China | Recruiting |
| Shanghai Pulmonary Hospital, Tongji University School of Medicine | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02889666